Investigators at Johns Hopkins have found a known genetic pathway to be active in many difficult-to-treat pediatric brain tumors called low-grade gliomas, potentially offering a new target for the treatment of these cancers. In laboratory studies, researchers found that the pathway, called mammalian target of rapamycin (mTOR), was highly active in pediatric low-grade gliomas, and that mTOR activity could be blocked using an experimental drug, leading to decreased growth of these tumors. "We think mTOR could function as an Achilles heel," says study co-author Eric Raabe, M.D., Ph.D...
via Health News from Medical News Today Read More Here..
No comments:
Post a Comment